Latest Breaking News On - இரத்தம் மூளை தடை - Page 6 : comparemela.com

Nascent Biotech Inc.: Nascent Biotech Earns US Patent for Crossing Blood-Brain Barrier SAN DIEGO, CA / ACCESSWIRE / March 2, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ( Nascent Biotech , Nascent , or the Company ), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is excited to announce that the Company has officially received allowance for a Method-of-Use patent by the US Patent and Trademark Office ( USPTO ) for their primary asset, Pritumumab ( PTB ). Specifically, the patent approval is related to PTB s ability to cross the Blood-Brain Barrier ( BBB ). The recent patent allowance recognizes PTB s ability to act as a monotherapy, as well as its potential to act as a conjugate, bringing other therapies across the BBB.

Sean carrickExchange commissionTrademark officeNascent biotech incSyracuse universitySecurities exchangeNascent biotech inc formCompany orphan drug designationNascent biotechBlood brain barrierOrphan drugSecurities actSecurities exchange actPrivate litigation reform actசீன் கேரிக்பரிமாற்றம் தரகு